1. Introduction {#sec1}
===============

*Lycopodium clavatum*(LC) is a dry whole grass of*Lycopodium japonicum*Thunb.; it has been widely used to anti-inflammatory \[[@B1]\], antioxidant, and antimicrobial actions \[[@B2]\] and inhibits acetylcholinesterase activity \[[@B3]--[@B5]\], meanwhile, it has antioxidative, antiproliferative, and biochemical effects for HepG2 cells \[[@B6]\]. In recent years, literature reports of LC pay more attention to analyzing component in*vitro*. LC mainly contains alkaloids \[[@B7]\] and triterpenoids \[[@B8]--[@B11]\]. Alkaloids are divided into four types with the structural characteristics, including lycopodine, lycodine, fawcettimine, and miscellaneous. Four types of mother nucleus all have the same configuration, so it is inferred that there is a common biological origin and transformation relationship between them \[[@B12], [@B13]\]. So far, there have been few reports on the chemical constituents of LC, and there is almost no research on the blood components in the body. Therefore, it is especially important for the chemical composition of LC in*vivo* and in*vitro*. At present, LC-MS is often used to analyze and determine the component of traditional Chinese medicine, especially the technology of UPLC-Q-TOF/MS \[[@B14], [@B15]\]. UPLC-Q-TOF/MS combined with multiple data processing approaches can improve efficiency and obtain abundant information, which can be utilized as a practical model for the study of component \[[@B16], [@B17]\]. The combination of the technology has the advantages of high efficiency, wide molecular mass range, high sensitivity, low error rate, and high reproducibility \[[@B18], [@B19]\]. In this work, a rapid method will be established for the compounds analysis of LC in*vitro* and in*vivo* by the ultra high performance liquid chromatography (UPLC) with quadrupole-time-of-flight mass spectrometry combined with multiple data-processing approaches, which can be used to further analyze the chemical composition in*vivo* and in*vitro*.

2. Methods and Materials {#sec2}
========================

2.1. Chemicals and Materials {#sec2.1}
----------------------------

*Lycopodium clavatum* was purchased from Beijing Huamiao Pharmaceutical Co. Ltd. It was identified as a dry whole grass of*Lycopodium japonicum*Thunb. by Professor Tianxiang Li from the College of Traditional Chinese Medicine of Tianjin University of Traditional Chinese Medicine. Methanol and acetonitrile (HPLC grade) were obtained from Sigma-Aldrich (America). Formic acid (HPLC grade) was purchased from Aladdin (America). Water was acquired from Wahaha (China). Ethanol (analysis grade) was purchased from Beijing Chemical Works (China). Male SD rats (200 ± 10g) were obtained from Beijing Huakangkang Biotechnology Co. Ltd.

2.2. Preparation of Lycopodium clavatum Samples In Vitro {#sec2.2}
--------------------------------------------------------

*Lycopodium clavatum* were added 10 times and 6 times 75% (*v/v*) ethanol, respectively, and were reflux extracted twice for 1 h each time. After being extracted, the extract was filtered and condensed to 1 g/mL. The concentrate was diluted to 10mg/mL by water with acetonitrile: 0.1% formic acid=1:1 (*v/v*) and through 0.22*μ*m filter membranes before analysis.

2.3. Animal Experiments {#sec2.3}
-----------------------

Male SD rats were acclimatized for 1 week before the experiment and collected blank blood. The suspension solution of*Lycopodium clavatum* was intragastrical administered at a dose of 10.8 g/kg for 3 days. After the last administration, the rats were collected blood by orbital vein at 15 min, 1 h, 4 h, and 8 h. All samples were centrifuged at 3,000 rpm for 15 min at 4°C and the plasma supernatant was pipetted.

2.4. Preparation of Plasma Samples In Vivo {#sec2.4}
------------------------------------------

For analysis, plasma was consolidated including the different blood collection points and 500*μ*L plasma was added 1 mL acetonitrile for protein precipitation. After vortexed vigorously for 1 min, the samples were centrifuged at 13, 000 rpm for 15 min at 4°C and pipetted plasma supernatant. 1 mL acetonitrile was added to the residue and the above operation was repeated one time. Two-part supernatants were combined and was evaporated to dried under N~2~ at 45°C. The residue was dissolved with 100*μ*L methanol, vortex-mixed for 1 min before being centrifuged at 13,000 rpm at 4°C for 15 min and then pipetted plasma supernatant for analysis.

2.5. Chromatographic Analysis {#sec2.5}
-----------------------------

The supernatant of sample was using A Waters ACQUITY I Class UPLC coupled to a Waters Xevo G2 Q TOF mass spectrometer, where the parameters were as follows. The chromatographic column was ACQUITY UPLC HSS T3 Column (2.1×100 mm, 1.8*μ*m, Waters Corporation, America). Mobile phases consisted of acetonitrile with 0.1% formic acid (phase A) and ultrapure water with 0.1% formic acid (phase B). Whole analysis process, runtime was 25min, the flow rate was set at 0.2 mL/min, and the temperature of the column was set at 40°C. The linear elution gradient program was used as follows: 0.5-1.5 min, 99--90% B; 1.5-4 min, 90-85% B; 4-8 min, 85-70% B; 8-9 min, 70-50% B; 9-11.5min, 50-20% B; 11.5-14 min, 20-0% B; 14-17 min, 0%B; 17-18 min, 0-99%B. The injection volume was set at 5*μ*L.

2.6. MS Conditions {#sec2.6}
------------------

An UPLC-Q-TOF/MS (waters, America) instrument is equipped with both positive and negative ESI source for sample analysis. The samples were measured from 50 to 1,000 mass-to-charge ratios (*m/z*) and the temperature of nitrogen was set to 350°C. The temperature of dissolvent was set to 80°C and the gas flow was set to 600 L/h. The capillary voltage was set to 3.0kV in positive ion mode, and it was set to 2.5 kV in negative ion mode.

2.7. Data Processing {#sec2.7}
--------------------

A rapid analysis of the extract of*Lycopodium clavatum* was carried out to obtain the retention time and the exact molecular weight of each component. The possible elemental composition was obtained through the MassLynx V4.1 workstation, and only those formulas with an error less than 10 ppm were accepted. The probable molecular formulas were matched with the relevant literature and databases such as SciFinder and MassBank. Meanwhile, to combine with MS and MS/MS information inferred the compound and its structure.

Raw spectrometric data were processed by MassLynx software (version 4.1, Waters Co., Cicero, America) and converted to a data matrix contain sample name, t-*m/z* and peak intensity. Data was further processed, including peak matching, peak alignment, and normalization, before multivariate analysis. Multivariate analysis was performed using a combination of principal component analysis (PCA) and the orthogonal projection to least-squared discriminant analysis (OPLS-DA) by SIMCA-P software (version 12.0), and then was further performed using*t*-test for Microsoft Excel software (version 2010). Metabolites were retained in the model based on a combination of variable importance in projection (VIP) greater than 1.0 and P value of less than 0.05.

MetaboLynx XS version 4.1 (Waters, Milford, America) can be used to find the unknown drug metabolites in*vivo*. Biotransformation reactions were set according to its different structure and the peak intensity threshold of 40 with tolerance was set at 0.05 Da. The result of possible metabolites and its biotransformation reactions were determined by the relevant literature and MS and MS/MS information.

3. Results and Discussion {#sec3}
=========================

3.1. Establishment of Compounds Database {#sec3.1}
----------------------------------------

To quickly and easily identify the compounds of*Lycopodium clavatum*, we established compounds database by collecting information of literature in ten years \[[@B7]--[@B11], [@B20]--[@B24]\] and searching web databases including Pubmed, SciFinder, and MassBank. The database includes 121 prototype compounds of*Lycopodium clavatum*that was shown in [Table S1](#supplementary-material-1){ref-type="supplementary-material"}, including name, molecular formula, molecular weight, and structure, to support the results of identification for further analysis in*vitro* and in*vivo*.

3.2. UHPLC--MS Analysis and Identification of Lycopodium clavatum In Vitro {#sec3.2}
--------------------------------------------------------------------------

Under the above MS and chromatographic conditions, the chromatogram of the base peak ion (BPI), the extract sample of*Lycopodium clavatum* was shown in [Figure 1](#fig1){ref-type="fig"}. According to the chromatogram, the baseline was stable and the chromatographic peaks were well separated, indicating that the various components of*Lycopodium clavatum* extract could be well separated in the data collection range.

The potential compounds were identified by comparing the information of MS and MS/MS; meanwhile, the result was associated with the relevant literature and databases for further determination. For Examples, the precise molecular weight was 366.2274 and the retention time was 7.89 min. The main fragment ions that were analyzed by the MS/MS screening were observed at*m/z* 348\[M+H-H~2~O\] ^+^, 288\[M+H -C~2~O~2~H~4~\] ^+^, 228\[M+H-C~4~O~4~H~8~\]^+^ in the positive ion spectrum. Based on MS and MS/MS data obtained and the analysis of elemental composition, the molecular formula of the ion was speculated of C~20~H~31~NO~5~. Combining with literature \[[@B24]\] it was inferred from acetyllycofawcine. Mass spectrum and proposed fragmentation pathway of acetyllycofawcine were shown in [Figure 2](#fig2){ref-type="fig"}. Finally, a total of 30 compounds were identified (characteristic peaks were labeled on the BPI chromatographic), including 21 alkaloids, 7 triterpenoids, and 2 other classes compound. The detailed information of compound name, molecular weight, molecular formula, and characteristic peak was shown in [Table 1](#tab1){ref-type="table"}.

3.3. Multivariate Statistical Analysis and Identification of Plasma Sample after Oral Lycopodium clavatum In Vivo {#sec3.3}
-----------------------------------------------------------------------------------------------------------------

In order to analyze the compounds of*Lycopodium clavatum* in plasma, the two groups were compared between the plasma sample of*Lycopodium clavatum* group and the control group that the chromatogram of BPI was shown in [Figure 3](#fig3){ref-type="fig"}, and then multivariate statistical analysis was used to further discover the prototype compounds in*vivo*.

PCA is a chemometric method that uses the idea of dimensionality reduction to transform multiple indicators into several comprehensive indicators with little information loss. In the PCA score ([Figure 4](#fig4){ref-type="fig"}), it could be observed that the plasma samples of drug-administered group and blank group were divided into two discrete groups, indicating that there was a significant difference in the drug-administered group and blank group. In order to further analyze the metabolic differences between the blank group and the drug-administered group in plasma samples, an in-depth analysis of the data (OPLS-DA) is required. According to the OPLS-DA score ([Figure 4](#fig4){ref-type="fig"}), it was clearly observed that the two groups plasma samples were divided into 2 discrete groups, which was better than the score of PCA. VIP value reflects the contribution of the variable in the classification. The larger the VIP value, the greater the contribution of the variable to the entire model classification. Generally, VIP value is greater than 1 as the characteristic variable of the metabolic. The value of VIP greater than 1 was screened and further analyzed. Finally, a total of 12 compounds were identified by the data of MS, MS/MS information, and the relevant literature and databases. They were lycojaponicumin C (6), huperzine E (8), des-N-methyl-*α*-obscurine (10), *α*-obscurine (11), lycopodine (13), 8*β*-acetoxy-12*β*-hydroxy-lycopodine or 8*β*-acetoxy-11*α*-hydroxy-lycopodine or 8*β*-hydroxy-11*α*- Acetoxylycopodine (14), lycodoline (16), *α*-lofoline or fawcettiine (17), acetylfawcettiine (20), japonicumin B or lycoclavanin (23), 3*R*, 21*α*, 24-trihydroxyserrat-14-en-16-one (24) and lycojaponicuminol C (26). Among them, *α*-obscurine (11) and lycodoline (16) were identified by comparison with the information of the standard, including retention time, MS and MSMS data. Next, the more standard will be purchased and used to further qualitative analysis of the compounds of*Lycopodium clavatum*.

3.4. Metabolites Identified Using MetaboLynx Tool {#sec3.4}
-------------------------------------------------

After the drug gets into the body, some components exist as the form of prototype, but most of them are structurally modified based on the original drug components, such as methylation and glutathione conjugation. The metabolite is structurally similar to the prototype drug and has characteristic mass spectrometry fragmentation of the prototype drug, so the structure of the metabolite can be inferred by characteristic fragment between the prototype and metabolite. Using MetaboLynx XS to process the data to analyze the plasma samples, most of the potential metabolites were identified. Finally, 5 metabolites were detected from the*Lycopodium clavatum.* The molecular weight of lycojaponicumin C (6) was 274.1811 and the formula was C~17~H~23~NO~2~. The precise molecular weight of M1 was 260.1653 that had a neutral loss of 14 Da compared with lycojaponicumin C (6) and the main fragment ions was 167, 158, and 125 that were the same as the main fragment ions of lycojaponicumin C (6); it is inferred that M1 is a metabolite of the demethylation of the lycojaponicumin C. Finally, a total of 5 metabolites were identified the same way. M2 is a metabolite of the methylation of the palhinine A, M3 is a metabolite of the methylation of the (15*R*)-14,15-dihydroepilobscurinol, M4 is a metabolite of the methylation of lycodoline, and M5 is a metabolite of the demethylation of *α*-lofoline. The detailed information of prototype, metabolite name, molecular weight, and molecular formula was given in [Table 2](#tab2){ref-type="table"}.

4. Conclusion {#sec4}
=============

In this work, we demonstrated a systematic and reliable analytical method using UPLC--Q-TOF-MS coupled with multiple data processing approaches for rapidly screening and identifying the chemical constituents of*Lycopodium clavatum* both in*vitro* and in*vivo*. In*vitro*, 30 peaks were characterized in 75% ethanol extract of*Lycopodium clavatum.* In*vivo*, 17 peaks were characterized in rat plasma that including 12 prototype compounds and 5 metabolites. Methylation and demethylation are the main transformation reactions of*Lycopodium clavatum* in rat plasma. This work could be helpful to understand the complex compounds of*Lycopodium clavatum* and further analyze the pharmacological studies of active compounds.
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###### 

Table S1: The database of 121 prototype compounds of Lycopodium clavatum.

###### 

Click here for additional data file.

![ESI base peak ion (BPI) chromatogram of the extract sample of*Lycopodium clavatum* extracts analyzed by UPLC--Q-TOF/MS in both positive (a) and negative (b) ion mode.](ECAM2019-5165029.001){#fig1}

![The mass spectra of acetyllycofawcine analyzed by UHPLC--Q-TOF-MS. the MS spectrum (a); the MSMS spectrum (b); proposed fragmentation pathways of acetyllycofawcine (c).](ECAM2019-5165029.002){#fig2}

![ESI base peak ion (BPI) chromatogram of the plasma sample of*Lycopodium clavatum* extracts analyzed by UPLC--Q-TOF/MS in both positive (a) and negative (b) ion mode; ESI base peak ion (BPI) chromatogram of the control plasma sample of*Lycopodium clavatum* extracts analyzed by UPLC--Q-TOF/MS in both positive (c) and negative (d) ion mode.](ECAM2019-5165029.003){#fig3}

![Multivariate statistical analysis and identification of plasma sample of*Lycopodium clavatum*. PCA of*Lycopodium clavatum* group vs. control group in positive mode (a) and negative mode (b); 3D-OPLS-DA of*Lycopodium clavatum* group vs. control group in positive mode (c) and negative mode (d).](ECAM2019-5165029.004){#fig4}

###### 

Identification of the components from *Lycopodium clavatum* in *vitro*.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NO.   t~R~(min)   Measured Mass (*m*/*z*)   Fragment ions (*m*/*z*)   Formula           Error (ppm)   Identification
  ----- ----------- ------------------------- ------------------------- ----------------- ------------- -------------------------------------------------------------------------------------------------------------------------
  1     3.8002      278.1756                  260, 162, 134             C~16~H~23~NO~3~   0             8*β*-hydroxylycoposerramine

  2     4.1863      266.2119                  248, 230, 202             C~16~H~27~NO~2~   0.38          aeacetylfawcettiine

  3     4.6209      292.1914                  274, 203, 135             C~17~H~25~NO~3~   0.34          palhinine A

  4     4.6343      273.1963                  243, 200, 186             C~17~H~24~N~2~O   1.46          obscurinene

  5     4.9963      296.185                   278, 260, 234             C~16~H~25~NO~4~   4.05          4*α*,8*β*,12*β*-trihydroxylycopodine

  6     5.1711      274.1811                  231, 167, 158             C~17~H~23~NO~2~   1.46          lycojaponicumin C

  7     5.2178      262.1807                  234, 206, 164             C~16~H~23~NO~2~   0             lycopoclavamine A

  8     5.2195      260.1661                  246, 24, 216              C~16~H~21~NO~2~   3.84          huperzine E \[[@B4]\]

  9     5.3981      280.1912                  262, 244, 163             C~16~H~25~NO~3~   0.36          6*α*,8*β*-dihydroxylycopodine or 4*α*,8*β*-dihydroxylycopodine

  10    5.5543      261.1966                  245, 202, 188             C~16~H~24~N~2~O   0.38          des-N-methyl-*α*-obscurine

  11    5.8878      275.2125                  244, 188, 148             C~17~H~26~N~2~O   0.73          *α*-obscurine

  12    6.0787      278.212                   260, 217, 189             C~17~H~27~NO~2~   0             (15*R*)-14,15-dihydroepilobscurinol

  13    6.2025      248.2016                  230, 145, 105             C~16~H~25~NO      0.81          lycopodine

  14    6.4302      322.2037                  244, 216, 176             C~18~H~27~NO~4~   5.9           8*β*-acetoxy-12*β*-hydroxy-lycopodine or 8*β*-acetoxy-11*α*-hydroxy-lycopodine or 8*β*-hydroxy-11*α*-acetoxy-lycopodine

  15    6.4922      246.1854                  218, 176, 124             C~16~H~23~NO      1.62          anhydrolycodoline

  16    6.5863      264.1966                  228, 242, 191             C~16~H~25~NO~2~   0.76          lycodoline

  17    6.7897      308.2226                  248, 230, 159             C~18~H~29~NO~3~   0             *α*-lofoline

  18    7.3916      276.1962                  218, 166, 150             C~17~H~25~NO~2~   0.72          lycoflexine

  19    7.8795      366.2274                  348, 288, 228             C~20~H~31~NO~5~   3.82          acetyllycofawcine

  20    8.2908      350.2324                  290, 230                  C~20~H~31~NO~4~   2.28          acetylfawcettiine

  21    8.5172      195.066                   167, 152, 115             C~10~H~10~O~4~    1.54          ferulic acid

  22    10.2069     505.3513                  487, 263, 199             C~30~H~48~O~6~    3.17          16-oxolyclanitin

  23    11.0118     489.3571                  471\. 453, 345            C~30~H~48~O~5~    1.84          japonicumin B or lycoclavanin

  24    12.1919     473.362                   102,111,167               C~30~H~48~O~4~    2.32          3*R*,21*α*,24-trihydroxyserrat-14-en-\
                                                                                                        16-one

  25    12.6387     475.377                   457, 410, 237             C~30~H~50~O~4~    3.58          Lycoclaninol \[[@B4]\] or japonicumin A

  26    13.0973     461.362                   443,441,102               C~29~H~48~O~4~    2.38          lycojaponicuminol C

  27    14.2839     445.3667                  279,427,319               C~29~H~48~O~3~    3.37          26-nor-8-oxo-*α*-onocerin

  28    15.3438     457.3664                  439,397                   C~30~H~48~O~3~    3.93          lycojaponicuminol A

  29    15.5437     459.3828                  441,398,397               C~30~H~50~O~3~    2.18          3-epilycoclavanol or\
                                                                                                        3*β*,21*β*,24-3-trihydroxyserrat-14-ene or\
                                                                                                        3*α*,21*β*,24-4-trihydroxyserrat-14-ene

  30    16.1058     603.4045^\[M-H\]^         116,132,134               C~39~H~56~O~5~    0.66          lycojaponicuminol D
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Identification of the metabolites from *Lycopodium clavatum* in *vivo*.

  NO.   t~R~(min)   Measured Mass (*m*/*z*)   Metabolite Name   Formula           Error (ppm)   Prototype
  ----- ----------- ------------------------- ----------------- ----------------- ------------- -------------------------------------
  M1    5.2         260.1653                  demethylation     C~16~H~21~NO~2~   1             lycojaponicumin C
  M2    6.95        306.2077                  methylation       C~18~H~27~NO~3~   2.6           palhinine A
  M3    9.17        292.2287                  methylation       C~18~H~29~NO~2~   3.7           (15*R*)-14,15-dihydroepilobscurinol
  M4    7.12        278.2127                  methylation       C~17~H~27~NO~2~   2.6           lycodoline
  M5    3.57        294.2076                  demethylation     C~17~H~27~NO~3~   2.4           *α*-lofoline
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